In this video, Motley Fool health care analyst David Williamson discusses what investors should look for in Vertex's upcoming earnings report and what the biotech has in store for 2013, including a collaboration with Johnson & Johnson.
The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.